Related Experiment Video
Updated: Jul 30, 2026
A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
Hepatoma-derived growth factor is associated with reduced sensitivity to irradiation in esophageal cancer
A Matsuyama1, H Inoue, K Shibuta
1Department of Surgery, Medical Institute of Bioregulation, Kyushu University, 4546 Tsurumihara, Beppu 874-0838, Japan.
Abstract:
Radiotherapy is a useful component of treatment for esophageal cancer. Identification of the genes that are differentially expressed between radiosensitive and radioresistant cancer cells is important for predicting clinical effectiveness of radiotherapy. We established human esophageal cancer cell lines resistant to X-ray. Using differential display, we obtained one gene that was expressed in radiosensitive cells but was rarely expressed in radioresistant cells, and that gene was identical with hepatoma-derived growth factor (HDGF), an acidic polypeptide with mitogenic activity for fibroblasts. The semiquantitative reverse transcription-PCR assay confirmed that HDGF mRNA expression was reduced in established radioresistant cells, and its reduction was associated with reduced sensitivity to irradiation. Radiotherapy was more effective in clinical cases with high HDGF mRNA expression compared with cases with low expression (P < 0.05). The findings demonstrate that HDGF may play an important role in radiosensitivity, and it could be a novel marker predicting effectiveness of radiotherapy in clinical cases.
Insights
Hepatoma-derived growth factor (HDGF) is expressed in radiosensitive esophageal cancer cells but not in radioresistant ones. High HDGF mRNA levels predict better radiotherapy effectiveness in patients.
Area of Science:
- Oncology
- Molecular Biology
- Radiotherapy Research
Background:
- Radiotherapy is crucial for esophageal cancer treatment.
- Predicting patient response to radiotherapy is essential for effective treatment planning.
- Understanding gene expression differences between radiosensitive and radioresistant cancer cells can identify predictive markers.
Purpose of the Study:
- To identify genes differentially expressed between radiosensitive and radioresistant human esophageal cancer cells.
- To investigate the role of hepatoma-derived growth factor (HDGF) in radiosensitivity.
- To evaluate HDGF as a potential predictive marker for radiotherapy effectiveness in esophageal cancer.
Main Methods:
- Establishment of human esophageal cancer cell lines resistant to X-ray irradiation.
- Differential display technique to identify differentially expressed genes.
- Semiquantitative reverse transcription-polymerase chain reaction (RT-PCR) to confirm gene expression levels.
- Correlation analysis of HDGF mRNA expression with clinical radiotherapy outcomes.
Main Results:
- Hepatoma-derived growth factor (HDGF) was identified as a gene expressed in radiosensitive cells but rarely in radioresistant cells.
- HDGF mRNA expression was significantly reduced in radioresistant esophageal cancer cell lines.
- Reduced HDGF expression correlated with decreased sensitivity to irradiation.
- Clinical data showed that radiotherapy was more effective in patients with high HDGF mRNA expression compared to those with low expression (P < 0.05).
Conclusions:
- Hepatoma-derived growth factor (HDGF) plays a significant role in determining radiosensitivity in esophageal cancer.
- HDGF is a potential novel biomarker for predicting the clinical effectiveness of radiotherapy in esophageal cancer patients.
More Related Videos
Related Concept Videos
02:38Mitogens and the Cell Cycle
01:24Regulation of Angiogenesis and Blood Supply